Recent Finacing
Recent Raise
BriSTAR Immunotech develops and industrializes cell‑therapy drugs via STAR‑T and enTCR‑T platforms, advancing pipelines for hematologic malignancies, solid tumors and viral infections through First‑in‑Human clinical studies and manufacturing scale-up.
